Search

Your search keyword '"Rahma, Osama E."' showing total 298 results
Start Over Author "Rahma, Osama E."
298 results on '"Rahma, Osama E."'

1. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

Author

Till, Jacob E., McDaniel, Lee, Chang, Changgee, Long, Qi, Pfeiffer, Shannon M., Lyman, Jaclyn P., Padrón, Lacey J., Maurer, Deena M., Yu, Jia Xin, Spencer, Christine N., Gherardini, Pier Federico, Da Silva, Diane M., LaVallee, Theresa M., Abbott, Charles, Chen, Richard O., Boyle, Sean M., Bhagwat, Neha, Cannas, Samuele, Sagreiya, Hersh, Li, Wenrui, Yee, Stephanie S., Abdalla, Aseel, Wang, Zhuoyang, Yin, Melinda, Ballinger, Dominique, Wissel, Paul, Eads, Jennifer, Karasic, Thomas, Schneider, Charles, O’Dwyer, Peter, Teitelbaum, Ursina, Reiss, Kim A., Rahma, Osama E., Fisher, George A., Ko, Andrew H., Wainberg, Zev A., Wolff, Robert A., O’Reilly, Eileen M., O’Hara, Mark H., Cabanski, Christopher R., Vonderheide, Robert H., and Carpenter, Erica L.

Published
2024
Full Text
View/download PDF

2. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.

Author

Spencer, Kristen, Pappas, Leontios, Baiev, Islam, Maurer, Jordan, Bocobo, Andrea Grace, Zhang, Karen, Jain, Apurva, De Armas, Anaemy Danner, Reyes, Stephanie, Le, Tri Minh, Rahma, Osama E, Stanton, Jennifer, DeLeon, Thomas T, Roth, Marc, Peters, Mary Linton B, Zhu, Andrew X, Lennerz, Jochen K, Iafrate, A John, Boyhen, Kylie, VanCott, Christine, Roberts, Lewis R, Lindsey, Stacie, Horick, Nora, Goff, Laura Williams, Mody, Kabir, Borad, Mitesh J, Shroff, Rachna T, Kelley, Robin Kate, Javle, Milind M, and Goyal, Lipika

Subjects
Bile Ducts, Intrahepatic, Humans, Cholangiocarcinoma, Bile Duct Neoplasms, Prognosis, Risk Factors, Retrospective Studies, Patient Safety, Liver Cancer, Digestive Diseases - (Gallbladder), Rare Diseases, Liver Disease, Clinical Trials and Supportive Activities, Cancer, Clinical Research, Digestive Diseases, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundTreatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of adjuvant, liver-directed, targeted, and investigational therapies.MethodsThis multicenter collaboration included patients with ICC or ECC treated at 1 of 8 participating institutions. Retrospective data were collected on risk factors, pathology, treatments, and survival. Comparative statistical tests were 2-sided.ResultsAmong 1039 patients screened, 847 patients met eligibility (ICC = 611, ECC = 236). Patients with ECC were more likely than those with ICC to present with early stage disease (53.8% vs 28.0%), undergo surgical resection (55.1% vs 29.8%), and receive adjuvant chemoradiation (36.5% vs 4.2%) (all P

Published
2023

3. Acute kidney injury in patients treated with immune checkpoint inhibitors

Author

Gupta, Shruti, Short, Samuel AP, Sise, Meghan E, Prosek, Jason M, Madhavan, Sethu M, Soler, Maria Jose, Ostermann, Marlies, Herrmann, Sandra M, Abudayyeh, Ala, Anand, Shuchi, Glezerman, Ilya, Motwani, Shveta S, Murakami, Naoka, Wanchoo, Rimda, Ortiz-Melo, David I, Rashidi, Arash, Sprangers, Ben, Aggarwal, Vikram, Malik, A Bilal, Loew, Sebastian, Carlos, Christopher A, Chang, Wei-Ting, Beckerman, Pazit, Mithani, Zain, Shah, Chintan V, Renaghan, Amanda D, De Seigneux, Sophie, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel Sanghoon, Rangarajan, Sunil, Deshpande, Priya, Coppock, Gaia, Eijgelsheim, Mark, Seethapathy, Harish, Lee, Meghan D, Strohbehn, Ian A, Owen, Dwight H, Husain, Marium, Garcia-Carro, Clara, Bermejo, Sheila, Lumlertgul, Nuttha, Seylanova, Nina, Flanders, Lucy, Isik, Busra, Mamlouk, Omar, Lin, Jamie S, Garcia, Pablo, Kaghazchi, Aydin, Khanin, Yuriy, Kansal, Sheru K, Wauters, Els, Chandra, Sunandana, Schmidt-Ott, Kai M, Hsu, Raymond K, Tio, Maria C, Mothi, Suraj Sarvode, Singh, Harkarandeep, Schrag, Deborah, Jhaveri, Kenar D, Reynolds, Kerry L, Cortazar, Frank B, Leaf, David E, Salem, Joe-Elie, Bagnis, Corinne Isnard, Rahma, Osama E, Mothi, Suraj S, Selamet, Umut, Chang, Weiting, Hirsch, Jamie S, Sakhiya, Vipulbhai, Stalbow, Daniel, Wu, Sylvia, Cennamo, Armando, Papa, Sophie, Rigg, Anne, Shaunak, Nisha, Kibbelaar, Zoe A, and Benesova, Karolina

Subjects
Kidney Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Renal and urogenital, Good Health and Well Being, Acute Kidney Injury, Aged, Cohort Studies, Female, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Male, Middle Aged, Risk Factors, immunotherapy, CTLA-4 antigen, programmed cell death 1 receptor, ICPi-AKI Consortium Investigators
Abstract

BackgroundImmune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer.MethodsWe collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI.ResultsICPi-AKI occurred at a median of 16 weeks (IQR 8-32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3-10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI.ConclusionsPatients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.

Published
2021

4. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerPD-L1/CTLA-4 Inhibition with Radiation for Colorectal Cancer

Author

Monjazeb, Arta M, Giobbie-Hurder, Anita, Lako, Ana, Thrash, Emily M, Brennick, Ryan C, Kao, Katrina Z, Manuszak, Claire, Gentzler, Ryan D, Tesfaye, Anteneh, Jabbour, Salma K, Alese, Olatunji B, Rahma, Osama E, Cleary, James M, Sharon, Elad, Mamon, Harvey J, Cho, May, Streicher, Howard, Chen, Helen X, Ahmed, Mansoor M, Mariño-Enríquez, Adrian, Kim-Schulze, Seunghee, Gnjatic, Sacha, Maverakis, Emanual, Marusina, Alina I, Merleev, Alexander A, Severgnini, Mariano, Pfaff, Kathleen L, Lindsay, James, Weirather, Jason L, Ranasinghe, Srinika, Spektor, Alexander, Rodig, Scott J, Hodi, F Stephen, and Schoenfeld, Jonathan D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Radiation Oncology, Clinical Trials and Supportive Activities, Colo-Rectal Cancer, Clinical Research, Immunotherapy, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Biomarkers, CTLA-4 Antigen, Colorectal Neoplasms, Combined Modality Therapy, Gene Expression Profiling, Humans, Immune Checkpoint Inhibitors, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Radiation Dose Hypofractionation, Treatment Outcome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeProspective human data are lacking regarding safety, efficacy, and immunologic impacts of different radiation doses administered with combined PD-L1/CTLA-4 blockade.Patients and methodsWe performed a multicenter phase II study randomly assigning patients with metastatic microsatellite stable colorectal cancer to repeated low-dose fractionated radiation (LDFRT) or hypofractionated radiation (HFRT) with PD-L1/CTLA-4 inhibition. The primary endpoint was response outside the radiation field. Correlative samples were analyzed using multiplex immunofluorescence (IF), IHC, RNA/T-cell receptor (TCR) sequencing, cytometry by time-of-flight (CyTOF), and Olink.ResultsEighteen patients were evaluable for response. Median lines of prior therapy were four (range, 1-7). Sixteen patients demonstrated toxicity potentially related to treatment (84%), and 8 patients had grade 3-4 toxicity (42%). Best response was stable disease in 1 patient with out-of-field tumor shrinkage. Median overall survival was 3.8 months (90% confidence interval, 2.3-5.7 months). Correlative IF and RNA sequencing (RNA-seq) revealed increased infiltration of CD8+ and CD8+/PD-1+/Ki-67+ T cells in the radiation field after HFRT. LDFRT increased foci of micronuclei/primary nuclear rupture in two subjects. CyTOF and RNA-seq demonstrated significant declines in multiple circulating immune populations, particularly in patients receiving HFRT. TCR sequencing revealed treatment-associated changes in T-cell repertoire in the tumor and peripheral blood.ConclusionsWe demonstrate the feasibility and safety of adding LDFRT and HFRT to PD-L1/CTLA-4 blockade. Although the best response of stable disease does not support the use of concurrent PD-L1/CTLA-4 inhibition with HFRT or LDFRT in this population, biomarkers provide support that both LDFRT and HFRT impact the local immune microenvironment and systemic immunogenicity that can help guide future studies.

Published
2021

5. Profiling of Natural Killer Interactions With Cancer Cells Using Mass Cytometry

Author

Hallisey, Margaret, Dennis, Jenna, Gabriel, Elizabeth P., Masciarelli, Alyssa, Chen, Jiajia, Abrecht, Charlotte, Brainard, Martha, Marcotte, William M., Dong, Han, Hathaway, Emma, Tarannum, Mubin, Vergara, Juliana A., Schork, Abigail N., Tyan, Kevin, Tarantino, Giuseppe, Liu, David, Romee, Rizwan, Rahma, Osama E., Severgnini, Mariano, Hodi, F. Stephen, and Baginska, Joanna

Published
2023
Full Text
View/download PDF

6. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer

Author

George, Thomas J, Franke, Aaron J, Chakravarthy, A Bapsi, Das, Prajnan, Dasari, Arvind, El‐Rayes, Bassel F, Hong, Theodore S, Kinsella, Timothy J, Landry, Jerome C, Lee, James J, Monjazeb, Arta M, Jacobs, Samuel A, Raben, David, Rahma, Osama E, Williams, Terence M, Wu, Christina, Coleman, C Norman, Vikram, Bhadrasain, and Ahmed, Mansoor M

Subjects
Digestive Diseases, Cancer, Clinical Research, Patient Safety, Biotechnology, Colo-Rectal Cancer, Good Health and Well Being, Antineoplastic Agents, Immunological, B7-H1 Antigen, Biological Products, Colorectal Neoplasms, HSP90 Heat-Shock Proteins, Herpesvirus 1, Human, Humans, Immunotherapy, Mitogen-Activated Protein Kinases, Molecular Targeted Therapy, National Cancer Institute (U.S.), Protein Kinase C, Pyrimidine Nucleosides, Radiation-Sensitizing Agents, United States, abscopal effect, chemoradiotherapy, colorectal cancer, immunotherapy, precision radiation medicine, radiation biology, radiation therapy, radiosensitization, rectal cancer, targeted therapeutics, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

Colorectal cancer (CRC) represents a major public health problem as the second leading cause of cancer-related mortality in the United States. Of an estimated 140,000 newly diagnosed CRC cases in 2018, roughly one-third of these patients will have a primary tumor located in the distal large bowel or rectum. The current standard-of-care approach includes curative-intent surgery, often after preoperative (neoadjuvant) radiotherapy (RT), to increase rates of tumor down-staging, clinical and pathologic response, as well as improving surgical resection quality. However, despite advancements in surgical techniques, as well as sharpened precision of dosimetry offered by contemporary RT delivery platforms, the oncology community continues to face challenges related to disease relapse. Ongoing investigations are aimed at testing novel radiosensitizing agents and treatments that might exploit the systemic antitumor effects of RT using immunotherapies. If successful, these treatments may usher in a new curative paradigm for rectal cancers, such that surgical interventions may be avoided. Importantly, this disease offers an opportunity to correlate matched paired biopsies, radiographic response, and molecular mechanisms of treatment sensitivity and resistance with clinical outcomes. Herein, the authors highlight the available evidence from preclinical models and early-phase studies, with an emphasis on promising developmental therapeutics undergoing prospective validation in larger scale clinical trials. This review by the National Cancer Institute's Radiation Research Program Colorectal Cancer Working Group provides an updated, comprehensive examination of the continuously evolving state of the science regarding radiosensitizer drug development in the curative treatment of CRC.

Published
2019

7. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

Author

Leaf, Rebecca Karp, Ferreri, Christopher, Rangachari, Deepa, Mier, James, Witteles, Wesley, Ansstas, George, Anagnostou, Theodora, Zubiri, Leyre, Piotrowska, Zofia, Oo, Thein H, Iberri, David, Yarchoan, Mark, Salama, April KS, Johnson, Douglas B, Leavitt, Andrew D, Rahma, Osama E, Reynolds, Kerry L, and Leaf, David E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Rare Diseases, Hematology, Autoimmune Disease, Adolescent, Adult, Aged, Aged, 80 and over, Anemia, Hemolytic, Autoimmune, Female, Glucocorticoids, Hemoglobins, Humans, Immunosuppression Therapy, Male, Middle Aged, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is a rare, but often severe, complication of ICPis. We identified 14 patients from nine institutions across the United States who developed ICPi-AIHA. The median interval from ICPi initiation to development of AIHA was 55 days (interquartile range [IQR], 22-110 days). Results from the direct antiglobulin test (DAT) were available for 13 of 14 patients: 8 patients (62%) had a positive DAT and 5 (38%) had a negative DAT. The median pretreatment and nadir hemoglobin concentrations were 11.8 g/dL (IQR, 10.2-12.9 g/dL) and 6.3 g/dL (IQR, 6.1-8.0 g/dL), respectively. Four patients (29%) had a preexisting lymphoproliferative disorder, and two (14%) had a positive DAT prior to initiation of ICPi therapy. All patients were treated with glucocorticoids, with three requiring additional immunosuppressive therapy. Complete and partial recoveries of hemoglobin were achieved in 12 (86%) and 2 (14%) patients, respectively. Seven patients (50%) were rechallenged with ICPis, and one (14%) developed recurrent AIHA. Clinical and laboratory features of ICPi-AIHA were similar in DAT positive and negative patients. ICPi-AIHA shares many clinical features with primary AIHA; however, a unique aspect of ICPi-AIHA is a high incidence of DAT negativity. Glucocorticoids are an effective first-line treatment in the majority of patients with ICPi-AIHA, and most patients who are rechallenged with an ICPi do not appear to develop recurrence of AIHA.

Published
2019

8. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors

Author

Seethapathy, Harish, Street, Sarah, Strohbehn, Ian, Lee, Meghan, Zhao, Sophia H., Rusibamayila, Nifasha, Chute, Donald F., Gao, Xin, Michaelson, Marc D., Rahma, Osama E., Choueiri, Toni K., McGregor, Brad, Sonpavde, Guru, Salabao, Cristina, Kaymakcalan, Marina D., Wei, Xiao, Gupta, Shruti, Motwani, Shveta, Leaf, David E., Reynolds, Kerry L., and Sise, Meghan E.

Published
2021
Full Text
View/download PDF

9. The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma

Author

Pappas, Leontios, Baiev, Islam, Reyes, Stephanie, Bocobo, Andrea Grace, Jain, Apurva, Spencer, Kristen, Le, Tri Minh, Rahma, Osama E., Maurer, Jordan, Stanton, Jen, Zhang, Karen, De Armas, Anaemy Danner, Deleon, Thomas T., Roth, Marc, Peters, Mary Linton B., Zhu, Andrew X., Boyhen, Kylie, VanCott, Christine, Patel, Tushar, Roberts, Lewis R., Lindsey, Stacie, Horick, Nora, Lennerz, Jochen K., Iafrate, A. John, Goff, Laura Williams, Mody, Kabir, Borad, Mitesh J., Shroff, Rachna T., Javle, Milind M., Kelley, R. Katie, and Goyal, Lipika

Published
2023
Full Text
View/download PDF

10. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer

Author

Keller, Rachel B., Mazor, Tali, Sholl, Lynette, Aguirre, Andrew J., Singh, Harshabad, Sethi, Nilay, Bass, Adam, Nagaraja, Ankur K., Brais, Lauren K., Hill, Emma, Hennessey, Connor, Cusick, Margaret, Del Vecchio Fitz, Catherine, Zwiesler, Zachary, Siegel, Ethan, Ovalle, Andrea, Trukhanov, Pavel, Hansel, Jason, Shapiro, Geoffrey I., Abrams, Thomas A., Biller, Leah H., Chan, Jennifer A., Cleary, James M., Corsello, Steven M., Enzinger, Andrea C., Enzinger, Peter C., Mayer, Robert J., McCleary, Nadine J., Meyerhardt, Jeffrey A., Ng, Kimmie, Patel, Anuj K., Perez, Kimberley J., Rahma, Osama E., Rubinson, Douglas A., Wisch, Jeffrey S., Yurgelun, Matthew B., Hassett, Michael J., MacConaill, Laura, Schrag, Deborah, Cerami, Ethan, Wolpin, Brian M., Nowak, Jonathan A., and Giannakis, Marios

Published
2023
Full Text
View/download PDF

11. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes

Author

Sridharan, Vishwajith, Mino-Kenudson, Mari, Cleary, James M., Rahma, Osama E., Perez, Kimberly, Clark, Jeffrey W., Clancy, Thomas E., Rubinson, Douglas A., Goyal, Lipika, Bazerbachi, Fateh, Visrodia, Kavel H., Qadan, Motaz, Parikh, Aparna, Ferrone, Cristina R., Casey, Brenna W., Fernandez-Del Castillo, Carlos, Ryan, David Patrick, Lillemoe, Keith D., Warshaw, Andrew L., Krishnan, Kumar, and Hernandez-Barco, Yasmin G.

Published
2021
Full Text
View/download PDF

14. Supplementary Data 1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., primary, Cardot-Ruffino, Victoire, primary, Dias Costa, Andressa, primary, Katz, Matthew H.G., primary, Bauer, Todd W., primary, Nowak, Jonathan A., primary, Wolpin, Brian M., primary, Abrams, Thomas A., primary, Patel, Anuj, primary, Clancy, Thomas E., primary, Wang, Jiping, primary, Mancias, Joseph D., primary, Reilley, Matthew J., primary, Stucky, Chee-Chee H., primary, Bekaii-Saab, Tanios S., primary, Elias, Rawad, primary, Merchant, Nipun, primary, Slingluff, Craig L., primary, Rahma, Osama E., primary, and Dougan, Stephanie K., primary

Published
2024
Full Text
View/download PDF

15. Arm B count matrices 4 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., primary, Cardot-Ruffino, Victoire, primary, Dias Costa, Andressa, primary, Katz, Matthew H.G., primary, Bauer, Todd W., primary, Nowak, Jonathan A., primary, Wolpin, Brian M., primary, Abrams, Thomas A., primary, Patel, Anuj, primary, Clancy, Thomas E., primary, Wang, Jiping, primary, Mancias, Joseph D., primary, Reilley, Matthew J., primary, Stucky, Chee-Chee H., primary, Bekaii-Saab, Tanios S., primary, Elias, Rawad, primary, Merchant, Nipun, primary, Slingluff, Craig L., primary, Rahma, Osama E., primary, and Dougan, Stephanie K., primary

Published
2024
Full Text
View/download PDF

16. Data from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., primary, Cardot-Ruffino, Victoire, primary, Dias Costa, Andressa, primary, Katz, Matthew H.G., primary, Bauer, Todd W., primary, Nowak, Jonathan A., primary, Wolpin, Brian M., primary, Abrams, Thomas A., primary, Patel, Anuj, primary, Clancy, Thomas E., primary, Wang, Jiping, primary, Mancias, Joseph D., primary, Reilley, Matthew J., primary, Stucky, Chee-Chee H., primary, Bekaii-Saab, Tanios S., primary, Elias, Rawad, primary, Merchant, Nipun, primary, Slingluff, Craig L., primary, Rahma, Osama E., primary, and Dougan, Stephanie K., primary

Published
2024
Full Text
View/download PDF

17. Arm A count matrices 3 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., primary, Cardot-Ruffino, Victoire, primary, Dias Costa, Andressa, primary, Katz, Matthew H.G., primary, Bauer, Todd W., primary, Nowak, Jonathan A., primary, Wolpin, Brian M., primary, Abrams, Thomas A., primary, Patel, Anuj, primary, Clancy, Thomas E., primary, Wang, Jiping, primary, Mancias, Joseph D., primary, Reilley, Matthew J., primary, Stucky, Chee-Chee H., primary, Bekaii-Saab, Tanios S., primary, Elias, Rawad, primary, Merchant, Nipun, primary, Slingluff, Craig L., primary, Rahma, Osama E., primary, and Dougan, Stephanie K., primary

Published
2024
Full Text
View/download PDF

18. Table S1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., primary, Cardot-Ruffino, Victoire, primary, Dias Costa, Andressa, primary, Katz, Matthew H.G., primary, Bauer, Todd W., primary, Nowak, Jonathan A., primary, Wolpin, Brian M., primary, Abrams, Thomas A., primary, Patel, Anuj, primary, Clancy, Thomas E., primary, Wang, Jiping, primary, Mancias, Joseph D., primary, Reilley, Matthew J., primary, Stucky, Chee-Chee H., primary, Bekaii-Saab, Tanios S., primary, Elias, Rawad, primary, Merchant, Nipun, primary, Slingluff, Craig L., primary, Rahma, Osama E., primary, and Dougan, Stephanie K., primary

Published
2024
Full Text
View/download PDF

19. TCR raw data 2 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., primary, Cardot-Ruffino, Victoire, primary, Dias Costa, Andressa, primary, Katz, Matthew H.G., primary, Bauer, Todd W., primary, Nowak, Jonathan A., primary, Wolpin, Brian M., primary, Abrams, Thomas A., primary, Patel, Anuj, primary, Clancy, Thomas E., primary, Wang, Jiping, primary, Mancias, Joseph D., primary, Reilley, Matthew J., primary, Stucky, Chee-Chee H., primary, Bekaii-Saab, Tanios S., primary, Elias, Rawad, primary, Merchant, Nipun, primary, Slingluff, Craig L., primary, Rahma, Osama E., primary, and Dougan, Stephanie K., primary

Published
2024
Full Text
View/download PDF

20. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases

Author

Reid, Pankti, primary, Sandigursky, Sabina, additional, Song, Juhee, additional, Lopez-Olivo, Maria A., additional, Safa, Houssein, additional, Cytryn, Samuel, additional, Efuni, Elizaveta, additional, Buni, Maryam, additional, Pavlick, Anna, additional, Krogsgaard, Michelle, additional, Abu-Shawer, Osama, additional, Altan, Mehmet, additional, Weber, Jeffrey S., additional, Rahma, Osama E., additional, Suarez-Almazor, Maria E., additional, Diab, Adi, additional, and Abdel-Wahab, Noha, additional

Published
2023
Full Text
View/download PDF

21. Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma

Author

Hall, William A., primary, Li, Jiahe, additional, You, Y. Nancy, additional, Gollub, Marc J., additional, Grajo, Joseph R., additional, Rosen, Mark, additional, dePrisco, Greg, additional, Yothers, Greg, additional, Dorth, Jennifer A., additional, Rahma, Osama E., additional, Russell, Marcia M., additional, Gross, Howard M., additional, Jacobs, Samuel A., additional, Faller, Bryan A., additional, George, Sagila, additional, Al baghdadi, Tareq, additional, Haddock, Michael G., additional, Valicenti, Richard, additional, Hong, Theodore S., additional, and George, Thomas J., additional

Published
2023
Full Text
View/download PDF

22. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., additional, Cardot-Ruffino, Victoire, additional, Dias Costa, Andressa, additional, Katz, Matthew H.G., additional, Bauer, Todd W., additional, Nowak, Jonathan A., additional, Wolpin, Brian M., additional, Abrams, Thomas A., additional, Patel, Anuj, additional, Clancy, Thomas E., additional, Wang, Jiping, additional, Mancias, Joseph D., additional, Reilley, Matthew J., additional, Stucky, Chee-Chee H., additional, Bekaii-Saab, Tanios S., additional, Elias, Rawad, additional, Merchant, Nipun, additional, Slingluff, Craig L., additional, Rahma, Osama E., additional, and Dougan, Stephanie K., additional

Published
2023
Full Text
View/download PDF

26. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

Author

Spencer, Kristen, primary, Pappas, Leontios, additional, Baiev, Islam, additional, Maurer, Jordan, additional, Bocobo, Andrea Grace, additional, Zhang, Karen, additional, Jain, Apurva, additional, De Armas, Anaemy Danner, additional, Reyes, Stephanie, additional, Le, Tri Minh, additional, Rahma, Osama E, additional, Stanton, Jennifer, additional, DeLeon, Thomas T, additional, Roth, Marc, additional, Peters, Mary Linton B, additional, Zhu, Andrew X, additional, Lennerz, Jochen K, additional, Iafrate, A John, additional, Boyhen, Kylie, additional, VanCott, Christine, additional, Roberts, Lewis R, additional, Lindsey, Stacie, additional, Horick, Nora, additional, Goff, Laura Williams, additional, Mody, Kabir, additional, Borad, Mitesh J, additional, Shroff, Rachna T, additional, Kelley, Robin Kate, additional, Javle, Milind M, additional, and Goyal, Lipika, additional

Published
2023
Full Text
View/download PDF

28. Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Author

Yap, Timothy A., primary, Gainor, Justin F., primary, Callahan, Margaret K., primary, Falchook, Gerald S., primary, Pachynski, Russell K., primary, LoRusso, Patricia, primary, Kummar, Shivaani, primary, Gibney, Geoffrey T., primary, Burris, Howard A., primary, Tykodi, Scott S., primary, Rahma, Osama E., primary, Seiwert, Tanguy Y., primary, Papadopoulos, Kyriakos P., primary, Blum Murphy, Mariela, primary, Park, Haeseong, primary, Hanson, Amanda, primary, Hashambhoy-Ramsay, Yasmin, primary, McGrath, Lara, primary, Hooper, Ellen, primary, Xiao, Xiaoying, primary, Cohen, Heather, primary, Fan, Martin, primary, Felitsky, Daniel, primary, Hart, Courtney, primary, McComb, Rachel, primary, Brown, Karen, primary, Sepahi, Ali, primary, Jimenez, Judith, primary, Zhang, Weidong, primary, Baeck, Johan, primary, Laken, Haley, primary, Murray, Richard, primary, Trehu, Elizabeth, primary, and Harvey, Christopher J., primary

Published
2023
Full Text
View/download PDF

31. Supplemental Data legends from Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

Author

Duffy, Austin G., primary, Ma, Chi, primary, Ulahannan, Susanna V., primary, Rahma, Osama E., primary, Makarova-Rusher, Oxana, primary, Cao, Liang, primary, Yu, Yunkai, primary, Kleiner, David E., primary, Trepel, Jane, primary, Lee, Min-Jung, primary, Tomita, Yusuke, primary, Steinberg, Seth M., primary, Heller, Theo, primary, Turkbey, Baris, primary, Choyke, Peter L., primary, Peer, Cody J., primary, Figg, William D., primary, Wood, Brad J., primary, and Greten, Tim F., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

Author

Duffy, Austin G., primary, Ma, Chi, primary, Ulahannan, Susanna V., primary, Rahma, Osama E., primary, Makarova-Rusher, Oxana, primary, Cao, Liang, primary, Yu, Yunkai, primary, Kleiner, David E., primary, Trepel, Jane, primary, Lee, Min-Jung, primary, Tomita, Yusuke, primary, Steinberg, Seth M., primary, Heller, Theo, primary, Turkbey, Baris, primary, Choyke, Peter L., primary, Peer, Cody J., primary, Figg, William D., primary, Wood, Brad J., primary, and Greten, Tim F., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 2 from Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

Author

Duffy, Austin G., primary, Ma, Chi, primary, Ulahannan, Susanna V., primary, Rahma, Osama E., primary, Makarova-Rusher, Oxana, primary, Cao, Liang, primary, Yu, Yunkai, primary, Kleiner, David E., primary, Trepel, Jane, primary, Lee, Min-Jung, primary, Tomita, Yusuke, primary, Steinberg, Seth M., primary, Heller, Theo, primary, Turkbey, Baris, primary, Choyke, Peter L., primary, Peer, Cody J., primary, Figg, William D., primary, Wood, Brad J., primary, and Greten, Tim F., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Author

Monjazeb, Arta M., primary, Giobbie-Hurder, Anita, primary, Lako, Ana, primary, Thrash, Emily M., primary, Brennick, Ryan C., primary, Kao, Katrina Z., primary, Manuszak, Claire, primary, Gentzler, Ryan D., primary, Tesfaye, Anteneh, primary, Jabbour, Salma K., primary, Alese, Olatunji B., primary, Rahma, Osama E., primary, Cleary, James M., primary, Sharon, Elad, primary, Mamon, Harvey J., primary, Cho, May, primary, Streicher, Howard, primary, Chen, Helen X., primary, Ahmed, Mansoor M., primary, Mariño-Enríquez, Adrian, primary, Kim-Schulze, Seunghee, primary, Gnjatic, Sacha, primary, Maverakis, Emanual, primary, Marusina, Alina I., primary, Merleev, Alexander A., primary, Severgnini, Mariano, primary, Pfaff, Kathleen L., primary, Lindsay, James, primary, Weirather, Jason L., primary, Ranasinghe, Srinika, primary, Spektor, Alexander, primary, Rodig, Scott J., primary, Hodi, F. Stephen, primary, and Schoenfeld, Jonathan D., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

Author

Duffy, Austin G., primary, Ma, Chi, primary, Ulahannan, Susanna V., primary, Rahma, Osama E., primary, Makarova-Rusher, Oxana, primary, Cao, Liang, primary, Yu, Yunkai, primary, Kleiner, David E., primary, Trepel, Jane, primary, Lee, Min-Jung, primary, Tomita, Yusuke, primary, Steinberg, Seth M., primary, Heller, Theo, primary, Turkbey, Baris, primary, Choyke, Peter L., primary, Peer, Cody J., primary, Figg, William D., primary, Wood, Brad J., primary, and Greten, Tim F., primary

Published
2023
Full Text
View/download PDF

39. Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC).

Author

George, Thomas J., primary, Yothers, Greg, additional, Rahma, Osama E., additional, Hong, Theodore S., additional, Russell, Marcia McGory, additional, You, Y. Nancy, additional, Parker, William, additional, Jacobs, Samuel A., additional, Lucas, Peter C., additional, Colangelo, Linda H., additional, Gollub, Marc J, additional, Hall, William A., additional, Kachnic, Lisa A., additional, Bajaj, Madhuri, additional, Gross, Howard M., additional, Peterson, Richard A., additional, Dorth, Jennifer Anne, additional, Vijayvergia, Namrata, additional, and Wolmark, Norman, additional

Published
2023
Full Text
View/download PDF

40. Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy.

Author

Mulcahy, Mary Frances, primary, Nimeiri, Halla, additional, Rahma, Osama E., additional, Wills, Jonathan, additional, Del Rosario, Kristian, additional, Lien, Justin, additional, Pelossof, Raphael, additional, Ahmed, Talal, additional, Guinney, Justin, additional, Beaubier, Nike, additional, Pietrantonio, Filippo, additional, Nakamura, Yoshiaki, additional, Huerga, Iker, additional, and Yoshino, Takayuki, additional

Published
2023
Full Text
View/download PDF

41. Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).

Author

Lyman, Jaclyn P., primary, Cabanski, Christopher R, additional, Maddock, Stephen, additional, Wolff, Robert A., additional, Wainberg, Zev A., additional, Ko, Andrew H., additional, Rahma, Osama E., additional, Fisher, George A., additional, Gabriel, Peter Edward, additional, Doucette, Abigail, additional, Zheng-Lin, Binbin, additional, Maloy, Molly A., additional, Dugan, Ute, additional, Fairchild, Justin P., additional, Spasic, Marko, additional, O'Donnell-Tormey, Jill, additional, Vonderheide, Robert H., additional, O'Hara, Mark H., additional, and O'Reilly, Eileen Mary, additional

Published
2023
Full Text
View/download PDF

44. Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving chemoimmunotherapy.

Author

Till, Jacob Edward, primary, McDaniel, Lee, additional, Pfeiffer, Shannon M., additional, Maurer, Deena M., additional, Yu, Jia, additional, Spencer, Christine, additional, Lyman, Jaclyn P., additional, Cabanski, Christopher R., additional, Da Silva, Diane M., additional, Abbott, Charles, additional, Boyle, Sean Michael, additional, Rahma, Osama E., additional, Fisher, George A., additional, Ko, Andrew H., additional, Wainberg, Zev A., additional, Wolff, Robert A., additional, O'Reilly, Eileen Mary, additional, O'Hara, Mark H., additional, Vonderheide, Robert H., additional, and Carpenter, Erica L., additional

Published
2022
Full Text
View/download PDF

45. Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1β and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).

Author

Oberstein, Paul Eliezer, primary, Rahma, Osama E., additional, Beri, Nina, additional, Stoll-D'Astice, Amy C., additional, Duliege, Anne-Marie, additional, Kawaler, Emily, additional, Dolgalev, Igor, additional, Werba, Gregor, additional, Cardot-Ruffino, Victoire, additional, Böllenrücher, Naïma, additional, Nazeer, Saloney, additional, Squires, Matthew, additional, Bar-Sagi, Dafna, additional, Wolpin, Brian M., additional, Dougan, Stephanie, additional, and Simeone, Diane M., additional

Published
2022
Full Text
View/download PDF

46. Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.

Author

Padrón, Lacey J., primary, Maurer, Deena M., additional, O'Hara, Mark H., additional, O'Reilly, Eileen Mary, additional, Wolff, Robert A., additional, Wainberg, Zev A., additional, Ko, Andrew H., additional, Fisher, George A., additional, Rahma, Osama E., additional, Lyman, Jaclyn P., additional, Cabanski, Christopher R., additional, Yu, Jia, additional, Pfeiffer, Shannon M., additional, Spasic, Marko, additional, Hollmann, Travis J, additional, Chen, Richard, additional, O'Donnell-Tormey, Jill, additional, Bucktrout, Samantha, additional, LaVallee, Theresa, additional, and Vonderheide, Robert H., additional

Published
2022
Full Text
View/download PDF

47. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Author

Yap, Timothy A., primary, Gainor, Justin F., additional, Callahan, Margaret K., additional, Falchook, Gerald S., additional, Pachynski, Russell K., additional, LoRusso, Patricia, additional, Kummar, Shivaani, additional, Gibney, Geoffrey T., additional, Burris, Howard A., additional, Tykodi, Scott S., additional, Rahma, Osama E., additional, Seiwert, Tanguy Y., additional, Papadopoulos, Kyriakos P., additional, Blum Murphy, Mariela, additional, Park, Haeseong, additional, Hanson, Amanda, additional, Hashambhoy-Ramsay, Yasmin, additional, McGrath, Lara, additional, Hooper, Ellen, additional, Xiao, Xiaoying, additional, Cohen, Heather, additional, Fan, Martin, additional, Felitsky, Daniel, additional, Hart, Courtney, additional, McComb, Rachel, additional, Brown, Karen, additional, Sepahi, Ali, additional, Jimenez, Judith, additional, Zhang, Weidong, additional, Baeck, Johan, additional, Laken, Haley, additional, Murray, Richard, additional, Trehu, Elizabeth, additional, and Harvey, Christopher J., additional

Published
2022
Full Text
View/download PDF

48. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma

Author

Singh, Prabhsimranjot, Toom, Sudhamshi, Avula, Akshay, Kumar, Vivek, and Rahma, Osama E

Subjects
locoregional therapies, Review, hepatocellular carcinoma, immunotherapy
Abstract

Locoregional therapies (LRTs) including radiofrequency ablation, surgical resection, and TACE, play a pivotal role in the treatment of early stage/locally advanced hepatocellular carcinoma (HCC). Besides their direct effect on tumor cells, LRTs also play an essential role in the immunomodulation of the tumor microenvironment which is of interest in the current era of cancer immunotherapy. In this review, we describe the HCC immune microenvironment and how it is affected by LRTs as described in multiple pre-clinical and clinical studies and provide the rationale for combining LRTs with immunotherapy.

Published
2020

49. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

Author

Rahma, Osama E, primary, Tyan, Kevin, additional, Giobbie-Hurder, Anita, additional, Brohl, Andrew S, additional, Bedard, Philippe L, additional, Renouf, Daniel J, additional, Sharon, Elad, additional, Streicher, Howard, additional, Hathaway, Emma, additional, Cunningham, Rachel, additional, Manos, Michael, additional, Severgnini, Mariano, additional, Rodig, Scott, additional, and Stephen Hodi, F, additional

Published
2022
Full Text
View/download PDF

50. A phase 1b study evaluating IL-1β and PD-1 targeting with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).

Author

Oberstein, Paul Eliezer, primary, Rahma, Osama E., additional, Beri, Nina, additional, Stoll-D'Astice, Amy C., additional, Duliege, Anne-Marie, additional, Nazeer, Saloney, additional, Squires, Matthew, additional, Bar-Sagi, Dafna, additional, Wolpin, Brian M., additional, Dougan, Stephanie, additional, and Simeone, Diane M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results